GlassScriptPhysician profile
Silvia Nilo
NPI 1043099781
$2,216.19
in general payments reported to CMS, 2019-2025
28 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $702 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.24 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $420.16 | 2024-2025 | Rybrevant, Carvykti, Talvey |
| Astellas Pharma US INC | $170.21 | 2024-2025 | Vyloy |
| Daiichi Sankyo INC. | $155.16 | 2024-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $134.22 | 2024-2025 | Keytruda, Lynparza |
| Pfizer INC. | $117.48 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $109.08 | 2024-2025 | |
| Puma Biotechnology, INC. | $104.77 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.36 | 2024-2025 | Iclusig, Ninlaro, Alunbrig |
| Sobi, INC | $101.52 | 2024-2025 | |
| Incyte Corporation | $85.25 | 2025 | Jakafi, Zynyz |
| Tersera Therapeutics LLC | $64.89 | 2025 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $63.89 | 2025 | |
| Genentech USA, INC. | $61.74 | 2025 | Itovebi, Phesgo |
| Alexion Pharmaceuticals, INC. | $52.01 | 2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $46.10 | 2025 | Enhertu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $44.31 | 2024 | Verzenio, Jaypirca |
| Genzyme Corporation | $42.05 | 2024 | |
| Abbvie INC. | $41.52 | 2025 | |
| Beone Medicines USA, INC. | $40.91 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $40.81 | 2025 | Libtayo |
| Exelixis INC. | $36.03 | 2025 | Cabometyx |
| Pharmaessentia USA Corporation | $31.02 | 2025 | Besremi |
| Adaptive Biotechnologies Corporation | $30.70 | 2025 | Clonoseq |
| Ipsen Biopharmaceuticals, INC | $27.46 | 2025 | Onivyde |
| Glaxosmithkline, LLC. | $26.01 | 2025 | Jemperli, Zejula |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.92 | 2024 | |
| Deciphera Pharmaceuticals INC. | $22.07 | 2024 | Qinlock |
| Recordati_rare_diseases_inc. | $17.54 | 2024 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silvia Nilo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.